ResMed (BSP:R1MD34) Cash And Cash Equivalents : R$1,185 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is ResMed Cash And Cash Equivalents?

ResMed's quarterly cash and cash equivalents declined from Sep. 2023 (R$1,032.68 Mil) to Dec. 2023 (R$1,030.17 Mil) but then increased from Dec. 2023 (R$1,030.17 Mil) to Mar. 2024 (R$1,184.74 Mil).

ResMed's annual cash and cash equivalents declined from Jun. 2021 (R$1,484.81 Mil) to Jun. 2022 (R$1,381.61 Mil) and declined from Jun. 2022 (R$1,381.61 Mil) to Jun. 2023 (R$1,106.12 Mil).

ResMed Cash And Cash Equivalents Historical Data

The historical data trend for ResMed's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed Cash And Cash Equivalents Chart

ResMed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash And Cash Equivalents

Get a 7-Day Free Trial

567.28

2,403.04

1,484.81

1,381.61

1,106.12

ResMed Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															1,187.01	1,106.12	1,032.68	1,030.17	1,184.74

ResMed Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

ResMed (BSP:R1MD34) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

ResMed Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of ResMed's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

ResMed (BSP:R1MD34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (BSP:R1MD34) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

RSMDF:USA RMD:USA RMEA:Germany RME:Germany RMEA:Germany RME:Germany RMD:Australia

Address

9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123

Website

https://www.resmed.com

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

ResMed (BSP:R1MD34) Headlines

No Headlines